No evidence for potential competition between human papillomavirus types in men

The Centers for Disease Control and Prevention Advisory Committee on Immunization Practices recently recommended that teenage boys be vaccinated against the human papillomavirus.

Human papillomavirus vaccines target the two most common types of the that cause : HPV 16 and 18. However, as more and more people are vaccinated, might this result in an increase of other types of HPV that cause cancer?

One of the first-ever, UNC-led epidemiological studies to examine HPV-type competition in men found little evidence for potential type competition. Previous studies in women report similar findings.  Their findings are published in the November 4, 2011 online edition of the Journal of Infectious Diseases.

Carcinogenic types of infection are the main cause of cervical cancer in women and are responsible for other genital cancers, including anal and penile cancer in men. It is also increasingly linked to head and neck cancers.

Viral type competition occurs when different types of a particular virus compete for dominance. The dominant HPV types in cervical cancer are the targets of the vaccines currently available. Study scientists did not find any other non-vaccine HPV types to be candidates for type-competition in men.

Jennifer S. Smith, PhD, MPH, is the study senior author.  She explained, “In our study, we wanted to know if any specific HPV type was less likely to be found with another HPV type, which could indicate possible competition of one type over another. Our data, among men prior to any introduction, do not suggest that one HPV type will dominate another.”

Anne F. Rositch, PhD, MSPH, the study first author, added, “We do not yet know if type competition occurs.  Although these data are reassuring, we will need pre- and post-vaccination surveillance data to determine if there is a change in the types of HPV causing cancer.”

Smith is an associate professor of epidemiology in the UNC Gillings School of Global Public Health and a member of UNC Lineberger Comprehensive Cancer Center. Rositch is a postdoctoral fellow at Johns Hopkins Bloomberg School of Public Health.

The study was conducted among 2702 HIV-seronegative men in Kisumu, Kenya who were tested for HPV types, and 57 percent of those tested positive for HPV infection.  The scientists identified positivity to over 40 types and studied them for potential type competition, but found none.

Related Stories

Cervical vaccine also protects against anal cancer risk

Aug 23, 2011

A vaccine routinely used to shield against cervical cancer caused by the human papillomavirus also reduces women's risk of anal cancer, a study published by the journal The Lancet Oncology on Tuesday says.

Recommended for you

Dallas hospital confirms first Ebola case in US

1 minute ago

A patient at a Dallas hospital has tested positive for Ebola, the first case of the disease to be diagnosed in the United States, federal health officials announced Tuesday.

First case of Ebola diagnosed in US

1 hour ago

The United States has diagnosed its first case of the deadly Ebola virus in a man who became infected in Liberia and traveled to Texas, US health officials said Tuesday.

Study finds acupuncture does not improve chronic knee pain

2 hours ago

Among patients older than 50 years with moderate to severe chronic knee pain, neither laser nor needle acupuncture provided greater benefit on pain or function compared to sham laser acupuncture, according to a study in the ...

Ebola outbreak nears end in Nigeria

2 hours ago

The Ebola outbreak in Nigeria is almost over, US health officials said Tuesday, in a rare sign of authorities turning the tide on the highly contagious disease that has killed more than 3,000 in West Africa.

User comments